Key Highlights

  • Fiscal first-quarter net sales rose 6% to USD 386.8 million from USD 363.9 million, with Mineral Nutrition up 17% and Performance Products up 16%.
  • Net income increased 11% to USD 29.5 million, or USD 0.72 per diluted share, compared with USD 26.5 million, or USD 0.65, in the quarter ended September 30, 2025.
  • Operating income fell 3% to USD 49.6 million from USD 51.3 million because selling, general and administrative expenses rose 15% to USD 78.9 million.
  • Adjusted EBITDA, a non-GAAP measure, rose 4% to USD 64.3 million from USD 61.9 million, while the Margin eased to 16.6% of net sales from 17.0%.

Mineral Nutrition and Performance Products Lead Phibro Animal Health (NASDAQ:PAHC) Sales

Phibro Animal Health (NASDAQ:PAHC) filed its fiscal first-quarter 2027 report on November 4, 2026, covering the three months ended September 30. The company makes animal health products, including medicated feed additives, plus mineral nutrition and performance products. Net sales rose USD 22.9 million to USD 386.8 million. Animal Health sales rose 3% to USD 293.0 million, with medicated feed additives up 6%, nutritional specialties down 2% and vaccines down 2%. Mineral Nutrition grew 17% to USD 73.6 million on Demand and higher prices for zinc oxide, copper and trace minerals, and Performance Products rose to USD 20.2 million.

Why Net Income Rose While Operating Income Dipped

Gross profit rose 7% to USD 128.5 million, lifting gross margin 30 basis points to 33.2%. Selling, general and administrative expenses climbed USD 10.4 million, partly because last year's figure was reduced by USD 3.8 million of insurance proceeds. Excluding such items, the company said SG&A rose 8%, mostly on employee costs in Animal Health. Net income still grew because net interest expense fell to USD 11.3 million, foreign currency swung to a USD 0.4 million gain from a USD 2.9 million loss, and the effective tax rate was 23.9% versus 26.9%. The Animal Health segment's Adjusted EBITDA slipped 1% to USD 73.9 million.

Tariff Refunds, Brazil Headwind and Chicago Heights Closure

The company received a full refund of USD 11.7 million of tariffs paid under the International Emergency Economic Powers Act, plus USD 0.4 million of interest, after the Supreme Court ruling in February 2026, and accepted another USD 1.7 million of claims. A USD 5.2 million drop in virginiamycin sales in Brazil, tied to regulatory developments, offset part of the medicated feed additive growth. In August 2026 management decided to close its Chicago Heights, Illinois Manufacturing plant, with about USD 5.0 million of severance and other costs expected and activities continuing through fiscal 2028. Cash and equivalents were USD 75.5 million, and the Equity statement shows dividends declared of USD 0.12 per share.

Where Things Stand

Profit rose because of below-the-line items, not operations. Phibro Animal Health (NASDAQ:PAHC) grew net income 11% on lower interest, a foreign currency gain and a lower tax rate, while operating income fell 3% as costs outpaced gross profit. Sales growth of 6% was driven mostly by Mineral Nutrition and Performance Products, which carry lower margins than Animal Health, and the Adjusted EBITDA margin slipped to 16.6%. The filing did not state numeric guidance for the year. Next markers are cost control, Brazil virginiamycin sales, the Chicago Heights closure costs and further Tariff refunds.